CONTENTS 目录 关于本报告 董事长兼首席执行官致辞 关于成都先导 附录 附录 1：ESG 绩效 附录 2：《上海证券交易 所上市公司自律监管指引 第 14 号——可持续发展 报告（试行）》索引 附录 3：《PSCI 负责任供 应链管理原则》索引 62 | 01 | | | | | --- | --- | --- | --- | | 02 | 可持续的 | | | | 03 | 公司治理 | | 负责任的 | | | 公司治理 | 08 | 价值链 | | | ESG 管治 | 10 | | | | 商业道德 | 14 | | | | 内控与风险管理 | 16 | | | 56 | | | | | 61 | | | | | 负责任的 | | | --- | --- | | 价值链 | | | 负责任供应链 | 19 | | 创新驱动 | 24 | | 产品质量与客户服务 | 29 | | 数据安全与隐私保护 | 32 | | 和谐共进的 | | | --- | --- | | 内外部生态 | 生态友好的 | | 员工权益 | 35 环境管理 | | 员工关爱与福利 | 38 | | 多元平等与包容 | ...

成都先导药物开发股份有限公司 关于终止重大资产重组的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都先导药物开发股份有限公司（以下简称"公司"）于 2025 年 4 月 1 日披 露了《成都先导药物开发股份有限公司关于筹划重大资产重组暨签署<股权收购 意向书>的提示性公告》（公告编号：2025-004），拟以现金方式受让股权的方式 合计取得南京海纳医药科技股份有限公司（以下简称"标的公司"）约 65%的股 权（以下简称"本次交易"）。《股权收购意向书》签署后，公司积极组织交易各 方推进本次交易，聘请了专业的中介机构对标的公司展开尽调，在此基础上，交 易各方对本次交易方案进行多次论证和协商，但未能就本次交易事项的核心条款 达成一致意见。为切实维护公司及全体股东利益，经公司充分审慎研究并与交易 对方友好协商，交易各方一致同意终止本次交易事项，本次重大资产重组事项终 止。现就有关情况公告如下： 一、本次筹划重大资产重组的基本情况 证券代码：688222 证券简称：成都先导 公告编号：2025-027 三、终止筹划 ...

Group 1 - The conference held in Chengdu focused on the role of mergers and acquisitions (M&A) in promoting industrial upgrades, with participation from representatives of listed companies, financial institutions, and various industry leaders [1] - Since the beginning of 2024, Sichuan listed companies have initiated or implemented 74 M&A transactions, totaling over 29 billion yuan, with 5 transactions starting after the new restructuring regulations were released on May 16, further stimulating market activity [3] - The new M&A regulations support cross-industry mergers, allow acquisitions of unprofitable assets, and aim to enhance regulatory tolerance, transaction efficiency, and intermediary service levels, facilitating companies to pursue growth through strategic acquisitions [3] Group 2 - Chengdu is actively promoting industrialization and the development of new productive forces, viewing M&A as a means for companies to quickly acquire core technologies, expand market reach, and optimize talent structures, while also serving as a driver for resource integration and modern industrial system construction [3] - The Chengdu Economic and Information Bureau is committed to assisting enterprises in utilizing M&A strategies and has initiated the establishment of a 2 billion yuan M&A fund focused on the health industry, marking the first such fund in Central and Western China [4] - In September 2024, Chengdu's Jiaozi Financial Holdings Group, in collaboration with Guojin Securities and other stakeholders, registered a 400 million yuan M&A fund, which is the first locally led fund focusing on M&A in strategic emerging industries such as advanced manufacturing and information technology [5]

成都先导药物开发股份有限公司 简式权益变动报告书 上市公司名称：成都先导药物开发股份有限公司 股票上市地点：上海证券交易所 股票简称：成都先导 股票代码：688222 信息披露义务人：安吉东方佳钰企业管理合伙企业（有限合伙） 注册地址：浙江省湖州市安吉县灵峰街道浮玉南路 61 号（金融大厦） 通讯地址：浙江省湖州市安吉县天目中路 531 号 权益变动性质：股份减少（持股比例下降至 5%） 签署日期：2025 年 6 月 23 日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国公司法》 《中华人民共和国证券法》、 《上市公司收购管理办法》 、《公开发行证 券的公司信息披露内容与格式准则第 15 号——权益变动报告书》及 其他相关法律、法规和部门规章的有关规定编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其 履行亦不违反信息披露义务人公司章程或内部规则中的任何条款，或 与之相冲突。 三、依据《中华人民共和国证券法》、 《上市公司收购管理办法》 和《公开发行证券的公司信息披露内容与格式准则第 15 号——权益 变动报告书》的规定，本报告书已全面披露信息披露义务人在成都先 导药物 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-026 成都先导药物开发股份有限公司 关于持股 5%以上股东权益变动 暨减持股份结果的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： （公告编号：2025-003），东方佳钰拟通过集中竞价交易或大宗交 易的方式减持其所持有的公司股份不超过 4,817,500 股，拟减持股份占 公司总股本的比例约为 1.20%，其中： （1）拟通过集中竞价交易的方式 减持的，自减持计划发布之日起 15 个交易日之后的 3 个月内（2025 年 3 月 24 日至 2025 年 6 月 23 日）实施，且任意连续 90 个自然日内 减持的股份总数不超过公司股份总数的 1%； （2）拟通过大宗交易的方 式减持的，自减持计划发布之日起 15 个交易日后的 3 个月内（2025 年 3 月 24 日至 2025 年 6 月 23 日）实施，且任意连续 90 个自然日内 减持的股份总数不超过公司股份总数的 2%。 公司于近日收到东方佳钰出具的《简式 ...

成都先导药物开发股份有限公司 简式权益变动报告书 上市公司名称：成都先导药物开发股份有限公司 股票上市地点：上海证券交易所 股票简称：成都先导 股票代码：688222 信息披露义务人：安吉东方佳钰企业管理合伙企业（有限合伙） 注册地址：浙江省湖州市安吉县灵峰街道浮玉南路 61 号（金融大厦） 1 幢 2304 号 29 室 通讯地址：浙江省湖州市安吉县天目中路 531 号 权益变动性质：股份减少（持股比例下降至 5%） 签署日期：2025 年 6 月 23 日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国公司法》、 《中华人民共和国证券法》、《上市公司收购管理办法》、《公开发行证 券的公司信息披露内容与格式准则第 15 号——权益变动报告书》及 其他相关法律、法规和部门规章的有关规定编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其 履行亦不违反信息披露义务人公司章程或内部规则中的任何条款，或 与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》 和《公开发行证券的公司信息披露内容与格式准则第 15 号——权益 变动报告书》的规定，本报告书已全面披露信 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-026 成都先导药物开发股份有限公司 关于持股 5%以上股东权益变动 暨减持股份结果的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 1 本次减持计划实施前股东持股的基本情况：成都先导药物开发股份有 限公司（以下简称"成都先导"或"公司"）股东安吉东方佳钰企业管理合 伙企业（有限合伙）（以下简称"东方佳钰"）持有公司股份 24,851,371 股，占公司总股本的 6.20%。上述股份为公司 IPO 前取得股份，该部 分股份于 2021 年 4 月 16 日起解禁上市流通。 本次减持计划的主要内容：公司于 2025 年 3 月 3 日在上海证券交易所 网站披露了《成都先导药物开发股份有限公司关于股东减持股份计划 公告》（公告编号：2025-003），东方佳钰拟通过集中竞价交易或大宗交 易的方式减持其所持有的公司股份不超过 4,817,500 股，拟减持股份占 公司总股本的比例约为 1.20%，其中：（1）拟通过集中竞价交易 ...

Core Viewpoint - On June 20, a total of 9 stocks on the Sci-Tech Innovation Board experienced block trading, with a cumulative transaction amount of 77.84 million yuan [1][2]. Group 1: Trading Overview - There were 14 block trades executed, totaling 3.64 million shares and an aggregate transaction value of 77.84 million yuan [1]. - The stock with the highest transaction amount was Hongsoft Technology, with 2 block trades totaling 448,000 shares and a transaction value of 17.92 million yuan [1]. - Other notable stocks in terms of transaction value included Zhuhai Guanyu and Delong Laser, with transaction amounts of 15.83 million yuan and 9.48 million yuan, respectively [1]. Group 2: Price and Performance Analysis - The average discount rates for block trades relative to the closing prices were highest for Zhongyou Technology, Hongsoft Technology, and Chengdu Xian Dao, with discount rates of 13.40%, 10.25%, and 9.49% respectively [1]. - The only stock with a premium was Transsion Holdings, which had a premium rate of 1.96% [1]. - The Sci-Tech 50 Index fell by 0.53%, with 170 stocks rising, accounting for 28.91% of the total [1]. - Among the stocks involved in block trading, the average decline was 2.04%, with Delong Laser and Jinghe Integration showing gains of 2.86% and 0.41%, while Zhongyou Technology, Jingye Intelligent, and Ankai Micro experienced declines of 7.58%, 3.87%, and 3.51% respectively [1]. Group 3: Institutional Participation - Among the block trades, there were 5 transactions involving institutional buyers or sellers across 4 stocks [2]. - The leading stocks for institutional buying were Hongsoft Technology and Delong Laser, with amounts of 10.92 million yuan and 9.48 million yuan respectively [2]. - The stocks with the highest institutional selling amounts were Zhongyou Technology and Jingye Intelligent, with amounts of 8.40 million yuan and 2.00 million yuan respectively [2]. Group 4: Capital Flow - Two stocks saw net inflows of capital, with Hongsoft Technology and Jinghe Integration receiving net inflows of 234,790 yuan and 1,310 yuan respectively [2]. - Conversely, the stocks with the highest net outflows included Zhongyou Technology, Chengdu Xian Dao, and Ankai Micro, with net outflows of 49.71 million yuan, 11.33 million yuan, and 10.03 million yuan respectively [2].

Summary of Key Points Core Viewpoint - The announcement details the share reduction by the major shareholder, Lhasa Economic and Technological Development Zone Huabo Medical Device Co., Ltd., which has reduced its stake in Chengdu Xian Dao Pharmaceutical Development Co., Ltd. by 2,000,000 shares, representing 0.50% of the total share capital. Group 1: Shareholder Background - Before the reduction plan, Huabo Medical held 46,770,579 shares, accounting for 11.67% of the total share capital, with these shares acquired prior to the company's IPO and released for trading on April 16, 2021 [1][2]. - Huabo Medical is identified as a direct shareholder holding more than 5% of the shares [2]. Group 2: Reduction Plan Implementation - The reduction plan was disclosed on March 3, 2025, with the intention to sell shares through centralized bidding from March 24, 2025, to June 23, 2025, with a limit of 1% of the total shares within any 90-day period [1]. - The actual reduction occurred between April 18, 2025, and June 19, 2025, with a total of 2,000,000 shares sold [2][4]. Group 3: Financial Details of the Reduction - The shares were sold at a price range of 14.66 to 17.79 yuan per share, resulting in a total reduction amount of 31,753,578.19 yuan [3]. - After the reduction, Huabo Medical holds 44,770,579 shares, which is 11.17% of the total share capital [3][4].

Summary of Chengdu XianDao Conference Call Company Overview - Chengdu XianDao focuses on drug discovery and development, leveraging DEL technology and AI to enhance efficiency in molecular optimization and project success rates [2][15][16]. Key Technologies and Platforms - **Halo Platform**: Integrates DEL technology with AI for high-throughput experiments and rapid molecular optimization, utilizing SAR data [2][15]. - **DMTA High-Throughput Molecular Optimization Platform**: Under development, includes Design, Make, Test, and Analyze phases for continuous molecular optimization [5][6]. - **AI in Drug Discovery**: The company has accumulated over 6,000 protein complex structures, 1.2 trillion compound structures, and nearly 1,000 target experimental data, forming a unique "lead model" for rapid compound testing [2][15]. Clinical Development - **HG146 Pipeline**: Targeting HDAC for solid tumors, currently in Phase II clinical trials with over 20 head and neck cancer patients enrolled. More data expected in Q4 2025 [2][10][26]. - **Second-Generation Small Molecule Inhibitor Project (3,918)**: Focused on AAA and AF diseases, with three preclinical candidates identified. The company seeks partnerships for further development [2][11]. Financial Performance - The biopharmaceutical sector performed well in Q1 2025, with stable year-on-year growth in R&D investment and commercial conversion rates [3][12][14]. - The company is undergoing a merger with a firm specializing in specialty formulations, which is expected to enhance innovation and market reach [4][14]. Collaborations and Market Position - Successful collaboration with Xiantong Bio in nucleic acid drug production, completing the first commercial project. However, the CDMO nucleic acid market is competitive with lower profit margins [4][30]. - The company is exploring international collaborations and has participated in events like the Boston Bio Conference to enhance its global presence [27]. Challenges and Risks - The company acknowledges the risks associated with early-stage projects and the competitive landscape in the CDMO market, particularly in nucleic acid drugs [4][30]. - AI technology has not yet reached widespread industrial application, with varying project outcomes [21]. Future Outlook - Chengdu XianDao aims to continue expanding its capabilities in AI-driven drug discovery and molecular optimization, with a focus on enhancing its commercial offerings and maintaining healthy growth rates [12][15][20].